HABS-HD - Core D - Omics Core

HABS-HD - 核心 D - 组学核心

基本信息

批准号：
10493848
负责人：
Robert A Rissman
金额：
$ 918.05万
依托单位：
UNIVERSITY OF NORTH TEXAS HLTH SCI CTR
依托单位国家：
美国
项目类别：
财政年份：
2022
资助国家：
美国
起止时间：
2022-09-30 至 2027-08-31
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10493848
关键词：
African American population Alzheimer&apos s Disease Alzheimer&apos s disease diagnosis Alzheimer’s disease biomarker Amyloid Amyloid beta-42 Bioinformatics Biological Assay Biological Markers Biostatistics Core Blood Clinical Trials Collaborations Collection Data Data Analyses Data Set Dementia Diagnostic Disease Ethnic group Fatty Acids Glycolysis Health Impaired cognition International Investigation Marker Discovery Mass Spectrum Analysis Methods Methylation Mexican Americans Modeling Molecular Weight Nerve Degeneration Neurons Not Hispanic or Latino Oxidative Phosphorylation Participant Pathology Pathway interactions Pharmaceutical Preparations Plasma Population Population Heterogeneity Prognosis Proteins Proteomics Protocols documentation Publishing Quality Control Research Personnel Sampling System Technology Update Validation Visit Work aging brain base biobank clinical diagnosis cohort exosome follow-up genome repository genome sequencing genome wide association study genomic data health disparity lipid metabolism metabolomics mild cognitive impairment novel novel marker oxidation racial and ethnic tau Proteins transcriptomics whole genome

项目摘要

HABS-HD OMICS CORE (CORE D) - ABSTRACT Biofluids, including blood and CSF, alone or in combination, may provide sensitive biomarkers for Alzheimer’s disease (AD) diagnosis, prognosis, and theragnosis. To date, however, no large-scale systematic multi-level “omics” study has been conducted in combination with AT(N) defined (amyloid [A], tau [T], neurodegeneration [N]) biomarkers among African Americans, Mexican Americans, and non-Hispanic whites. Our data suggests that (1) omics-based biomarkers vary across diverse populations, including plasma AT(N) biomarkers, (2) omics-based biomarkers can be highly accurate in detecting clinically diagnosed mild cognitive impairment (MCI) and dementia across populations, but (3) the profiles differ between racial/ethnic groups. More recently, our data suggests that a proteomic profile is accurate in detecting neurodegeneration, but again the profiles vary between racial/ethnic groups. Given the documented differences in AT(N) biomarkers by racial/ethnic groups, it is likely that multi-level omics investigations will highlight novel population-specific pathways for cognitive decline, MCI and AD. Additionally, with the recent FDA approval of a disease modifying amyloid drug, the data from the Omics Core (Core D) is more important than ever and can rapidly inform novel, appropriately tailored, clinical trials. Core D will oversee the collection, processing, assays, storage and distribution of samples to provide critical data to all Projects (Core – Project Interactions), Cores (Core-Core interactions), and to global investigators (Cross-Cohort Interactions). Aim 1: Generate high quality genomic data. Aim 2: Generate high quality proteomic data. Aim 3: Generate high quality exosome data. Aim 4: Generate high quality metabolomic data. Aim 5: Provide critical omics data for projects (Core-Core, Core-Project Interactions). Aim 6: Provide data and expertise to external investigators.

HABS-HD 组学核心（核心 D）- 摘要生物流体，包括血液和脑脊液，单独或组合，可以为阿尔茨海默病提供敏感的生物标志物然而，迄今为止，还没有大规模系统性多层次的疾病（AD）诊断、预后和治疗诊断。 “组学”研究与 AT(N) 定义（淀粉样蛋白 [A]、tau [T]、神经变性 [N]）我们的数据表明，非洲裔美国人、墨西哥裔美国人和非西班牙裔白人中的生物标志物。 (1) 基于组学的生物标志物在不同人群中存在差异，包括血浆 AT(N) 生物标志物，(2) 基于组学的生物标志物可以高度准确地检测临床诊断的轻度认知障碍 (MCI) 和不同人群的痴呆症，但 (3) 种族/族裔群体之间的情况有所不同。我们的数据表明蛋白质组图谱在检测神经退行性疾病方面是准确的，但同样的图谱鉴于不同种族/民族的 AT(N) 生物标志物存在记录差异。组，多层次组学研究可能会突出新的人群特异性途径此外，最近 FDA 批准了一种改善疾病的淀粉样蛋白药物，来自组学核心 (Core D) 的数据比以往任何时候都更加重要，并且可以快速提供新颖、适当的信息 Core D 将监督定制的临床试验的收集、处理、分析、储存和分发。向所有项目（核心-项目交互）、核心（核心-核心交互）提供关键数据的示例，目标 1：生成高质量的基因组数据。生成高质量的蛋白质组数据目标 3：生成高质量的外泌体数据目标 4：生成高质量的外泌体数据。目标 5：为项目（核心-核心、核心-项目）提供关键组学数据。目标 6：向外部调查人员提供数据和专业知识。